Suppr超能文献

心肌肌钙蛋白:从心肌梗死到慢性病。

Cardiac troponins: from myocardial infarction to chronic disease.

机构信息

BHF Centre of Research Excellence, The Rayne Institute, Cardiovascular Division, King's College London, London, UK.

Burdon Sanderson Cardiac Science Centre, Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK.

出版信息

Cardiovasc Res. 2017 Dec 1;113(14):1708-1718. doi: 10.1093/cvr/cvx183.

Abstract

Elucidation of the physiologically distinct subunits of troponin in 1973 greatly facilitated our understanding of cardiac contraction. Although troponins are expressed in both skeletal and cardiac muscle, there are isoforms of troponin I/T expressed selectively in the heart. By exploiting cardiac-restricted epitopes within these proteins, one of the most successful diagnostic tests to date has been developed: cardiac troponin (cTn) assays. For the past decade, cTn has been regarded as the gold-standard marker for acute myocardial necrosis: the pathological hallmark of acute myocardial infarction (AMI). Whilst cTn is the cornerstone for ruling-out AMI in patients presenting with a suspected acute coronary syndrome (ACS), elevated cTn is frequently observed in those without clinical signs indicative of AMI, often reflecting myocardial injury of 'unknown origin'. cTn is commonly elevated in acute non-ACS conditions, as well as in chronic diseases. It is unclear why these elevations occur; yet they cannot be ignored as cTn levels in chronically unwell patients are directly correlated to prognosis. Paradoxically, improvements in assay sensitivity have meant more differential diagnoses have to be considered due to decreased specificity, since cTn is now more easily detected in these non-ACS conditions. It is important to be aware cTn is highly specific for myocardial injury, which could be attributable to a myriad of underlying causes, emphasizing the notion that cTn is an organ-specific, not disease-specific biomarker. Furthermore, the ability to detect increased cTn using high-sensitivity assays following extreme exercise is disconcerting. It has been suggested troponin release can occur without cardiomyocyte necrosis, contradicting conventional dogma, emphasizing a need to understand the mechanisms of such release. This review discusses basic troponin biology, the physiology behind its detection in serum, its use in the diagnosis of AMI, and some key concepts and experimental evidence as to why cTn can be elevated in chronic diseases.

摘要

1973 年,肌钙蛋白生理上不同亚基的阐明极大地促进了我们对心脏收缩的理解。尽管肌钙蛋白在骨骼肌和心肌中都有表达,但肌钙蛋白 I/T 也有选择性地在心脏中表达的同工型。通过利用这些蛋白质中的心脏特异性表位,开发出了迄今为止最成功的诊断测试之一:心肌肌钙蛋白(cTn)检测。在过去的十年中,cTn 一直被认为是急性心肌坏死的金标准标志物:急性心肌梗死(AMI)的病理标志。虽然 cTn 是用于排除疑似急性冠状动脉综合征(ACS)患者 AMI 的基石,但在没有提示 AMI 临床症状的患者中,cTn 经常升高,通常反映“未知来源”的心肌损伤。cTn 在急性非 ACS 情况下以及慢性疾病中经常升高。目前尚不清楚为什么会出现这些升高;然而,由于慢性不适患者的 cTn 水平与预后直接相关,因此不能忽视这些升高。矛盾的是,由于检测特异性降低,由于 cTn 在这些非 ACS 情况下更容易检测到,因此需要考虑更多的鉴别诊断,这意味着检测灵敏度的提高。需要注意的是,cTn 对心肌损伤具有高度特异性,这可能归因于无数潜在原因,强调 cTn 是一种器官特异性而非疾病特异性的生物标志物。此外,使用高灵敏度检测在剧烈运动后检测到 cTn 升高令人不安。有研究表明肌钙蛋白的释放可能发生在心肌细胞坏死之前,这与传统观点相矛盾,强调需要了解这种释放的机制。本综述讨论了基本的肌钙蛋白生物学、其在血清中检测的生理学基础、在 AMI 诊断中的应用,以及一些关键概念和实验证据,说明为什么 cTn 在慢性疾病中会升高。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/280b/5852618/5d35953b6091/cvx183f1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验